Enterosgel Tube 225 g. - Relief from IBS Symptoms: Diarrhoea, Abdominal Pain, Bloating, Urgency | Irritable Bowel Syndrome Treatment | Acute Diarrhoea Relief

Product Information

Množstvo výhod, veľa pozitívnych hodnotení v recenziách od iných ľudí (samozrejmosťou sú aj opačné názory, čo je zrejmé), vynikajúce zloženie a vlastnosti (nevstrebáva sa a absorbuje len škodlivé látky, tie prospešné si nevšíma), ktoré neškodí ani malým deťom, čo viac si priať? For children 15+ and adults: 15-22.5g (1-1½ tablespoon or 1-1½ sachets) diluted in 200ml of water 3 times a day.

Following 8 weeks of open-label treatment, 349 patients completed the open-label phase. Comparison with secondary outcome data reported during the double-blind phase confirmed continued treatment effect for the same observed variables ( online supplemental files S7–S10). Mean days per week loperamide use fell in the Enterosgel group in contrast to the placebo (week 1: 0.83 vs 1.14, week 8: 0.77 vs 1.47) and continued to fall during open label (week 16: 0.68 vs 0.87), suggesting patients experienced a continued improvement in symptoms. Enterosgel: This is a tasteless gel that is mixed with water and patient’s drink. It is a type of treatment called an intestinal adsorbent and works in the gut by capturing harmful substances that can cause diarrhoea and removing them from the body in the stool. Patients received a tube containing the gel mixed in water, which they mixed into a glass of water and drank. comunque molto importante: evitare di tenerlo in frigo, utilizzare solo cucchiai in plastica, una volta aperta finire tutta la sua confezione senza conservarla. Contributors CAH is the author responsible for drafting the manuscript. PP acted as the Chief Investigator for the study and provided support in the recruitment, assisted with the study design and contributed to the manuscript. EM, AVK and RA assisted with the study design and contributed to the manuscript. VA conducted the statistical analyses and data interpretation and contributed to the manuscript. AK was responsible for the management and coordination of the study, conducted the literature search and oversaw data collection and management. All authors read and approved the final manuscript. WHO and Unicef claim that there are approximately two billion cases of diarrhoeal disease every year worldwide, and in children under 5 years of age, 1.9 million die from diarrhoea each year, most often in developing countries. Annually, in the UK, there are 17 million cases and 1 million physician consultations attributed to acute infectious diarrhoea. 1

Supplementary Data

The gel looks slightly cloudy and feels slightly powdery in the mouth but is easy to take – either on a spoon or stirred into water. This was a pragmatic study with flexible treatment instructions in an incremental dosing pattern, to allow participants to find the most appropriate dose to treat their symptoms. Such flexibility hindered our ability to find a set dosage scheme for maximal treatment benefit and as median treatment dose was only two doses per day across the study, this may have prevented patients from taking sufficient treatment to be classified as a responder. At the outset we recognised that this may be a limitation, but we wanted to provide as ‘real world’ a scenario as possible where patient treatment adherence varies, and IBS symptoms fluctuate over time. After 8 weeks all patients knew they then received Enterosgel in this Open label phase and reported the same things for another 8 weeks. The Enterosgel group had a higher percentage of patients (49%) with an improvement in their stool consistency compared to the placebo group (33%). Slightly more patients in the placebo group (9%) reported related side effects than in the Enterosgel group (7%).

uporabljate druge črevesne adsorbente, na primer pripravke, ki vsebujejo aktivno oglje, glino ali kaolin, se o tem posvetujte s svojim zdravnikom ali farmacevtom. Ta vam bo morda svetoval, da le-teh ne uporabljate sočasno z izdelkom ENTEROSGEL. The average number of stools per day, and the average bloating and urgency scores reported by patients, also improved more in the Enterosgel group than in the placebo group. Ethics approval The study obtained ethical approval from the North West—Lancaster Research Ethics Committee (16/NW/0818). Study was approved by the Health Research Authority (HRA), UK.Further clinical studies with Enterosgel are planned, for similar medical conditions that cause people to have long-term (chronic) diarrhoea. These include bile acid malabsorption and pelvic radiation disease. A study in children under 5 years with short-term (acute) diarrhoea will soon begin in The Gambia. Inovativni crevni adsorbent (enterosorbent) Enterosgelje organosilicijumov polimerni spoj porozne strukture i konzistencije gela. Safety: In this study, researchers found that people who took Enterosgel had slightly fewer, but the same type of side effects as the placebo.